Pinnacle Associates LTD Galapagos Nv Transaction History

Pinnacle Associates LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 23, 2020	SELL	$122.47 - $213.56 $202,075 - $352,374	-1,650 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$185.52 - $231.25 $963,219 - $1.2 Million	-5,192 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$143.0 - $274.03 $1,001 - $1,918	7 Added 0.14%	5,192 $1.02 Million
Q4 2019 Feb 03, 2020	BUY	$146.12 - $215.82 $3,653 - $5,395	25 Added 0.48%	5,185 $1.07 Million
Q3 2019 Nov 08, 2019	BUY	$130.44 - $187.64 $88,177 - $126,844	676 Added 15.08%	5,160 $788,000
Q2 2019 Aug 05, 2019	BUY	$111.45 - $128.93 $281,411 - $325,548	2,525 Added 128.89%	4,484 $578,000
Q1 2019 May 10, 2019	BUY	$89.61 - $117.78 $175,545 - $230,731	1,959 New	1,959 $231,000

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.58B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

Stay updated on Pinnacle Associates LTD with notifications on news.